Homepage 2020

is developing first-in-class therapies designed to reprogram the immune system... COUR Pharmaceuticals breakthrough nanoparticle technology has been shown to harness the immune system’s built-in learning abilities… ...COUR’s ...getting the body to recognize and tolerate the specific antigens or allergens that trigger destructive and often life-threatening immune activation. Slide To induce immune tolerance in autoimmune and allergic diseases, including: Slide Peanut Allergy Primary Biliary Cholangitis Immune Thrombocytopenia Purpura To induce immune tolerance in autoimmune and allergic diseases, including: Slide COUR has demonstrated rapid translation from bench to human proof of concept in less than 3 years.

COUR’s platform of immune-modifying nanoparticles treats the root cause of immune-mediated disease, unlike traditional approaches, which rely on toxic immune suppressants or avoidance strategies.

ACHIEVING IMMUNE TOLERANCE
First-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease

BROAD POTENTIAL IMPACT
Clinically validated platform with applications across a wide range of immune-mediated disease

 

Watch the video on COUR's reprogramming in autoimmune disease

Our Pipeline

UNMATCHED BREAKTHROUGH
COUR’s CNP-101 for celiac disease, partnered with Takeda, is the first therapy to induce antigen-specific immune tolerance in any autoimmune disease in humans.

Our Technology

COUR’s platform of immune-modifying nanoparticles treats the root cause of immune-mediated disease, unlike traditional approaches, which rely on toxic immune suppressants or avoidance strategies.